ERBB2 and breast carcinoma: Based on the published evidence available so far and their expert opinions, seven of eight panelists (87.5%) would consider treatment with T-DXd before SG in HR-negative/HER2-low patients (see Table 2), and they agree with the suggested treatment algorithm for HR-negative/HER2-low breast cancers shown in Figure 1B.